Skip to main content
Journal cover image

Effects of albiglutide on myocardial infarction and ischemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.

Publication ,  Journal Article
Krychtiuk, KA; Marquis-Gravel, G; Murphy, S; Alexander, KP; Chiswell, K; Green, JB; Leiter, LA; Lopes, R; Del Prato, S; Jones, WS; Granger, CB ...
Published in: Eur Heart J Cardiovasc Pharmacother
January 25, 2024

AIMS: Large outcome trials have demonstrated cardiovascular benefits of selected glucagon-like peptide-1 (GLP-1) receptor agonists. We examined coronary disease outcomes in the Harmony Outcomes trial of the GLP-1 receptor agonist albiglutide. METHODS AND RESULTS: Harmony Outcomes was an event-driven, multicenter, double-blind, placebo-controlled trial involving 9 463 patients > 40years of age with type-2 diabetes and established atherosclerotic cardiovascular disease. It tested the effects of albiglutide on the occurrence of a composite primary endpoint, consisting of cardiovascular death, myocardial infarction or stroke. Within this post-hoc analysis, the effects of albiglutide on myocardial infarction subtypes and other ischemic endpoints were analyzed.During the median-follow up of 1.6 years, a total of 421 patients (4.5%) experienced at least one myocardial infarction, with 72 patients having more than one event. Treatment with albiglutide reduced both first events (hazard ratio (HR)0.75 (0.62-0.91)) and overall events (HR0.75 (0.61-0.91)) as well as first type 1 (HR0.73 (0.57-0.92)) and type 2 myocardial infarctions (HR0.65 (0.46-0.92)). The effect of albiglutide treatment was consistent for ST-segment elevation (HR0.69 (0.38-1.26)) and non-ST elevation (HR0.86 (0.66-1.2) myocardial infarction. CONCLUSIONS: Treatment with the GLP-1 receptor agonist albiglutide resulted in a 25% relative risk reduction in myocardial infarction that was consistent for type of infarction and presence or absence of ST elevation. Our findings add novel information about the effects of GLP-1 receptor agonists on ischemic events in patients with type 2 diabetes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Heart J Cardiovasc Pharmacother

DOI

EISSN

2055-6845

Publication Date

January 25, 2024

Location

England

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Krychtiuk, K. A., Marquis-Gravel, G., Murphy, S., Alexander, K. P., Chiswell, K., Green, J. B., … Granger, C. B. (2024). Effects of albiglutide on myocardial infarction and ischemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvae006
Krychtiuk, Konstantin A., Guillaume Marquis-Gravel, Shannon Murphy, Karen P. Alexander, Karen Chiswell, Jennifer B. Green, Lawrence A. Leiter, et al. “Effects of albiglutide on myocardial infarction and ischemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.Eur Heart J Cardiovasc Pharmacother, January 25, 2024. https://doi.org/10.1093/ehjcvp/pvae006.
Krychtiuk KA, Marquis-Gravel G, Murphy S, Alexander KP, Chiswell K, Green JB, et al. Effects of albiglutide on myocardial infarction and ischemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial. Eur Heart J Cardiovasc Pharmacother. 2024 Jan 25;
Krychtiuk, Konstantin A., et al. “Effects of albiglutide on myocardial infarction and ischemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.Eur Heart J Cardiovasc Pharmacother, Jan. 2024. Pubmed, doi:10.1093/ehjcvp/pvae006.
Krychtiuk KA, Marquis-Gravel G, Murphy S, Alexander KP, Chiswell K, Green JB, Leiter LA, Lopes R, Del Prato S, Jones WS, McMurray JJV, Hernandez AF, Granger CB. Effects of albiglutide on myocardial infarction and ischemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial. Eur Heart J Cardiovasc Pharmacother. 2024 Jan 25;
Journal cover image

Published In

Eur Heart J Cardiovasc Pharmacother

DOI

EISSN

2055-6845

Publication Date

January 25, 2024

Location

England

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology